ArticleNature communications2025
Library-based virtual match-between-runs quantification in GlyPep-Quant improves site-specific glycan identification.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Strategies for in-depth and simultaneous analysis of N- and O-glycoproteome of platelets uncovering sex-specific signatures of human platelets.Analytical and bioanalytical chemistry · 2026Article
- A Protein-Centric Strategy Coupled with Match-Between-Run Glycoproteomics Enables Discovery of Robust Site-Specific Glycan Biomarkers for Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- GlycoTraitR: an R package for characterizing structural heterogeneity in N-linked glycoproteomics data.Bioinformatics advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Glycosylation changes are closely related to various diseases, including cancer. The quantitative analysis of site-specific glycans at proteomics scale remains challenging due to low glycopeptide spectra interpretation. Here, we present GlyPep-Quant, a tool for sensitive quantification and identification of site-specific glycans. Using a well-trained machine learning model, GlyPep-Quant quantified 25.1%-178.9% more site-specific glycans without missing values than pGlycoQuant, MSFragger-Glyco, and Skyline. To utilize identified information from previous large-scale dataset, an MS1 feature library-based "virtual match-between-runs" quantification scheme was developed, enabling over eightfold more site-specific glycan identification/quantification than conventional MS2-based methods. Enhanced coverage prompted the development of a glycoproteomic biomarker discovery method, involving calculation of site-specific glycan abundances ratios at the same glycosylation site, minimizing individual expression and experimental condition variability. Two pairs of site-specific glycan ratios on sites P01011-N127 and P08185-N96, were selected as high-performance biomarkers to classify gastric cancer (GC) from healthy controls (AUC > 0.95). Moreover, the two ratios performed well in distinguishing GC using an independent cohort by the library-based quantification strategy with diagnostic accuracy up to 85%. GlyPep-Quant is poised for broader glycoproteomic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.